Commonwealth Diagnostics International

02/21/2026

When "Gut-Healthy" Foods Trigger Symptoms

Your patient follows every wellness recommendation. Kombucha daily. Kimchi with lunch. Kefir smoothies. But instead of thriving, they're experiencing worse bloating, cramping, diarrhea, and reflux.

The clinical reality:

Fermented foods aren't universally beneficial. For patients with SIBO or histamine-producing gut bacteria (Morganella, Klebsiella, some Lactobacillus), these same foods feed bacterial overgrowth—triggering the exact inflammation and GI distress they're trying to resolve.

Why the same food can heal one patient and harm another:

Individual genes and microbiome composition determine response. When bacteria colonize the wrong location (small intestine instead of colon), fermentable substrates don't support gut health—they fuel overgrowth and symptom escalation.

The diagnostic challenge:

Without objective testing, it's impossible to distinguish which patients benefit from fermented foods and which experience harm. Symptoms alone can't reveal whether gas, bloating, and abdominal pain stem from SIBO, IMO, histamine intolerance, or carbohydrate malabsorption.

What breath testing provides:

Hydrogen and methane breath tests measure gas levels after substrate ingestion, identifying bacterial overgrowth (SIBO) or methanogen overgrowth (IMO) that drives food intolerance patterns. This objective data prevents trial-and-error dietary restrictions and reveals the microbial root cause.

How CDI supports precision nutrition:

✅ Non-invasive SIBO & IMO breath testing—at-home collection
✅ Carbohydrate malabsorption panels (lactose, fructose, sucrose)
✅ 24-hour turnaround for faster dietary decisions
✅ Real-time MyGI Gateway tracking for RD collaboration
✅ Comprehensive prep guides for accurate results

The shift in clinical practice:

From generic "eat fermented foods for gut health" → objective breath testing → personalized nutrition based on individual microbial activity.

When dietary recommendations are guided by gas profiles instead of wellness trends, patients stop suffering through foods that harm them.

Test the microbiome. Then personalize the diet.

📧 Questions about integrating breath testing into nutritional protocols? Contact Provider Relations at providerservices@commdx.com

02/19/2026

When Bloating Isn't Just Bloating

Your patient presents with chronic bloating and constipation. You've ruled out structural issues. IBS-C seems obvious—but what if it's not?

The diagnostic challenge:
Bloating + constipation could signal methane-producing archaea (IMO), not generic IBS. Symptoms alone can't tell you which one you're treating.

Why methane matters:
Methane doesn't just indicate microbial activity; it slows intestinal transit. Methane-producing archaea directly affect gut motility, explaining why constipation-dominant symptoms persist despite standard IBS treatments.
Treating symptom patterns without identifying methanogen overgrowth means managing effects—not causes.

The diagnostic marker:
A fasting single methane measurement (SMM) ≥10 ppm serves as a simple, non-invasive biomarker for IMO. This objective cutoff—validated with 100% specificity—differentiates methane-driven constipation from other functional GI disorders.

What this means for your workup:
✅ Non-invasive, at-home collection — no clinic visits required
✅ Clear diagnostic threshold — ≥10 ppm SMM indicates IMO, guiding targeted treatment
✅ 24-hour turnaround — faster decisions, reduced delays
✅ Real-time MyGI Gateway tracking — seamless result monitoring

The shift:
Symptom-based IBS-C diagnosis → objective methane testing → targeted IMO treatment.

When you know it's methane, you treat it differently.
CDI's hydrogen and methane breath testing provides diagnostic clarity to differentiate IMO from IBS-C, enabling personalized treatment instead of trial-and-error management.

Objective methane data → targeted treatment → symptom relief.

👉 Explore how CDI's methane breath testing differentiates IMO from other functional GI disorders at commdx.com.
📧 Questions? Contact Provider Relations at providerservices@commdx.com

02/16/2026

Your Trusted Partner for Functional GI Diagnostics

Functional GI disorders require more than symptom-based guesswork—they demand precise, objective diagnostics that reveal what's happening beneath the surface.

At Commonwealth Diagnostics International (CDI), we've specialized in breath testing for SIBO, IMO, and carbohydrate malabsorption for 13+ years, delivering diagnostic clarity that transforms patient care.

Why GI practices partner with CDI:

Comprehensive Breath Testing

Full range of breath tests for SIBO, IMO, and carbohydrate malabsorption (lactose, fructose, sucrose)—designed for both adults and children to ensure accurate diagnostics across your entire patient population.

Cutting-Edge Technology

Our proprietary MyGI Gateway platform provides access to all patient data in one place, streamlining order management, real-time kit tracking, and result retrieval—less time on logistics, more time treating patients.
Highest Industry Standards

ISO 13485-certified and FDA-registered tests with unmatched clinical support, educational resources, and prep compliance tools that optimize testing accuracy and patient adherence.

The CDI advantage:
✅ Non-invasive, at-home collection — easier for patients, fewer barriers
✅ 24-hour turnaround — fast results without treatment delays
✅ Real-time MyGI Gateway tracking — transparency from kit to result
✅ Comprehensive prep support — guides, videos, multi-language FAQs, automated reminders
✅ Provider Relations partnership — workflow optimization, metric reviews, clinical consultation
✅ CLIA-certified lab processing — research-backed, consensus-aligned methodology
Our commitment:

We deliver precise, reliable, non-invasive breath tests to identify and manage digestive distress and functional GI ailments. Whether diagnosing SIBO in celiac patients with recurrent symptoms, identifying IMO in constipation-dominant IBS, or ruling out carbohydrate malabsorption—CDI provides the diagnostic foundation for confident, evidence-based care.

Innovative technology + rigorous standards + clinical partnership = better patient outcomes.

👉 Explore CDI's diagnostic solutions at commdx.com
📧 Optimize your breath testing workflows: providerservices@commdx.com

02/14/2026

A patient with SIBO follows their doctor's advice to eat more fiber. Two weeks later, they're worse.

What went wrong?

Nothing—except the advice assumed all fiber affects all patients the same way. It doesn't.​

The Fiber Paradox

Fiber is essential for gut health—unless your gut can't handle it.

For patients with SIBO, IMO, or carbohydrate malabsorption, increasing fiber can worsen symptoms by feeding bacterial overgrowth or overwhelming deficient digestive enzymes.

Kate Scarlata, GI dietitian and leading FODMAP expert, explained this clearly in CDI's Modern Gastro Podcast: "Some fibers trigger inflammation in patients with specific microbiome imbalances. Universal fiber recommendations can be harmful depending on individual gut function".​

The result?

Patients follow "healthy" advice and feel worse. They assume something is wrong with them—when really, something is wrong with the one-size-fits-all recommendation.​

Diagnostic Clarity Enables Personalized Fiber Guidance

You can't personalize fiber recommendations without knowing what's happening in the gut.​

Breath testing provides that clarity:

SIBO/IMO testing reveals bacterial/archaeal overgrowth affecting fiber tolerance
Carbohydrate malabsorption tests (fructose, lactose, sucrose) identify which fiber-rich foods will be problematic​​

Armed with this data, GI-trained dietitians can recommend:
Soluble vs. insoluble fiber based on gut motility​
Low-FODMAP fiber sources during SIBO treatment
Specific fruits and vegetables that match the patient's absorption capacity
Gradual fiber reintroduction post-treatment​

Blanket advice → Some patients worsen.
Test first → Personalize fiber → Better tolerance, better outcomes.

Personalized dietary guidance requires two things: GI-trained expertise (dietitians who understand functional GI disorders) and objective diagnostic data (breath testing that reveals what's actually happening).​​

One without the other is guesswork.​

👉 Want to discuss how breath testing supports nutrition-based treatment in functional GI?

Email providerservices@commdx.com
and we work with GI dietitians and practices to ensure testing informs dietary interventions effectively.

🎧 Full podcast episode:
Kate Scarlata on Modern Gastro

02/11/2026

"I can't eat sugar" is what patients say. But which sugar?

Lactose, fructose, and sucrose are all sugars—but they're digested by different enzymes, found in different foods, and require different dietary modifications. When a patient says "sugar makes me sick," the first question should be: which one?​​

Malabsorption: Lactose
Enzyme Deficiency: Lactase
Common Food Sources: Milk, dairy products, cream-based foods
Prevalence 10% of Americans, up to 65% globally

Malabsorption: Fructose
Enzyme Deficiency: Fructose carriers (GLUT5)
Common Food Sources: Fruits, honey, high fructose corn syrup, some vegetables
Prevalence Increasingly common with processed food consumption

Malabsorption: Sucrose
Enzyme Deficiency: Sucrase & isomaltrase
Common Food Sources: Table sugar, sweet fruits, desserts
Prevalence Less common but often missed ​

Why Blanket "Sugar-Free" Diets Don't Work

When patients eliminate all sugars indiscriminately:

⚠️They restrict foods they could tolerate (unnecessary dietary burden)​
⚠️They may still consume the specific sugar they can't digest (symptoms persist)​
⚠️Nutritional variety suffers (especially problematic in pediatric patients)​
Compliance drops because restrictions feel excessive​

Breath testing solves this by identifying the specific carbohydrate malabsorption. Then dietary counseling becomes surgical, not scattershot.​

🟦A patient with fructose malabsorption can still enjoy dairy and table sugar—just needs to limit high-fructose fruits and avoid high fructose corn syrup.​

🟦A patient with lactose malabsorption can eat fruit and sweeteners freely—just needs lactose-free dairy or enzyme supplementation.​

🟦A patient with sucrose malabsorption may tolerate dairy and some fruits but needs to avoid table sugar and starchy foods.​

Specific testing → Targeted restriction → Better outcomes.

👉 Want to add carbohydrate malabsorption testing to your diagnostic approach? Email providerservices@commdx.com—we'll walk through ordering, patient prep, and result interpretation.

📘 Explore testing options: commdx.com/diagnostic-solutions

02/10/2026

A recent study and editorial in AJG revisit a question that sits at the heart of modern functional GI care:

When patients with disorders of gut–brain interaction (DGBI) say they’re “intolerant” to certain carbohydrates, how often is that backed by objective malabsorption—and does it matter clinically?

The answer from this work: carbohydrate malabsorption measured on standardized breath tests is common in DGBI and strongly linked to symptom burden and quality of life.

That’s important for anyone building a diagnostic pathway for chronic bloating, IBS-like symptoms, and other functional presentations—and it directly reinforces the diagnostic paradigm CDI uses in its carbohydrate malabsorption program.

Read the full evidence spotlight: https://commdx.com/carbohydrate-malabsorption-breath-testing-evidence-spotlight/

A new AJG study validates carbohydrate malabsorption measured on standardized breath tests is common in DGBI and strongly linked to symptom burden and quality of life.

02/08/2026

Most practices face three gaps in breath testing: unreturned kits, delayed results, and patients who don't follow prep protocols.

These aren't just operational frustrations—they're diagnostic delays.

When kits don't come back, results take too long, or prep isn't followed, patients wait longer for answers and treatment pathways stall.​​

CDI was designed to close those gaps.

How CDI Addresses the Three Gaps

Gap 1: Unreturned kits
Solution: Automated patient reminders, real-time MyGI Gateway tracking, and Patient Outreach team support to drive return ratios above 70%

Gap 2: Delayed results
Solution: 24-hour turnaround from lab receipt to reported results—treatment decisions happen faster​

Gap 3: Poor prep compliance
Solution: Multilingual prep videos, detailed FAQs, automated reminders, and live support so patients understand protocols before test day​​

Beyond that, CDI offers the full testing portfolio (SIBO, IMO, fructose, lactose, sucrose for adults and pediatrics), ISO 13485 certification, and a dedicated Provider Relations team for ordering, billing, and interpretation support.

When the system works seamlessly, diagnostic workflows improve—and patients get answers faster.​

Fewer unreturned kits + faster results + better prep compliance = more actionable diagnostic data.

👉 Want to see how your current return ratios and turnaround times compare?

Contact providerservices@commdx.com and we'll review your metrics and walk through how CDI's support system could reduce diagnostic delays in your practice.

📘 Learn more: commdx.com/diagnostic-solutions

02/06/2026

Your patient completes their SIBO breath test.

The results? Inconclusive. 😤

The test needs to be repeated—delaying diagnosis by weeks.

What went wrong? Most of the time, it's not the test. It's the preparation.

Why prep matters:

Breath tests measure hydrogen & methane gases produced by gut bacteria in response to a sugar substrate. But if recent food intake, medications, or incomplete fasting interfere, the results get skewed.

False positives: High-FODMAP meal the night before → residual fermentation elevates gas levels → test flags positive, but it's not SIBO

False negatives: Recent antibiotic use → bacterial activity suppressed → SIBO exists but test doesn't capture it

Inconclusive results: Patient doesn't follow fasting or timing protocols → data unreliable → test must be repeated

Preparation isn't just a suggestion—it's critical for test validity.
✓ 24-hour dietary restriction clears fermentable substrates
✓ 12-hour fast puts gut in resting state
✓ Medication restrictions prevent interference
✓ Precise timing captures fermentation accurately

Proper preparation → Accurate results → Confident diagnosis → Better outcomes.
📧 providerservices@commdx.com

02/03/2026

Three different GI practices walked into the lab. Each needed breath testing—but for completely different reasons.

Practice 1: Procedurally-Focused

A patient has chronic bloating and diarrhea. Before scheduling another endoscopy, the clinician orders a SIBO/IMO breath test. Result: positive for IMO. Treatment: targeted antibiotics, not another scope. The procedure is reserved for patients who truly need it.​​

Practice 2: Brain-Gut Axis Specialist

A patient with IBS-D has tried multiple diets and therapies. Symptoms persist. The clinician orders fructose and lactose breath tests to rule out malabsorption before attributing symptoms solely to motility or visceral hypersensitivity. Result: fructose malabsorption confirmed. Treatment becomes precise.

Practice 3: Comprehensive GI Care

A patient completed antibiotic treatment for SIBO. Symptoms improved but didn't fully resolve. The clinician orders a post-treatment breath test to confirm eradication. Result: hydrogen normalized but methane still elevated. Treatment adjusted to target IMO specifically.

One Tool, Three Applications

As Dr. Spiegel noted in CDI's Modern Gastro Podcast, GI is "this beautiful blend between surgery and internal medicine". That diversity means diagnostic tools need to flex—supporting procedural decisions, brain-gut axis insights, and comprehensive care pathways.​​

CDI's breath testing supports all three:

Pre-procedure clarity for intervention-focused practices​

Objective data for functional disorder specialists​

Treatment-response tracking for comprehensive care​

Your practice style shapes how you use breath testing—and that's exactly how it should work.​

👉 Want to discuss how breath testing fits your specific workflow? Email

providerservices@commdx.com—we'll walk through use cases tailored to your practice focus.

🎧 Hear more about GI's unique blend: Modern Gastro Podcast - A Guide to the Guidelines

02/02/2026

Thanks to Valerie Orsoni - LeBootCamp for running a SIBO/IMO Breath Test with us and sharing such a thoughtful breakdown of her results. 🙏

The question of hydrogen-enriched water is a great one — our lab team is actively exploring how it could affect breath test curves, so we can update future patient prep guidance. We’re all for ‘test, don’t guess’ and really appreciate you helping push the science and conversation forward.

01/30/2026

You’re treating an IBS patient empirically with antibiotics. They improve.

But would you have predicted that response before prescribing?

Not all IBS patients respond to antibiotics—but those who test positive for SIBO are more than twice as likely to show symptomatic improvement.​

A systematic review and meta‑analysis in the Journal of Neurogastroenterology and Motility evaluated whether IBS patients with SIBO respond better to antibiotics than IBS patients without SIBO. The findings were clear:

🔵IBS patients with SIBO had a 51% symptomatic response rate
🔵IBS patients without SIBO had a 23% response rate
🔵Relative risk of response: 2.07

This is the first study to demonstrate that a positive SIBO breath test predicts a higher likelihood of antibiotic response in IBS patients.​

Why This Matters for Treatment Decisions

Breath testing isn’t just a diagnostic tool—it’s a treatment predictor. When you identify SIBO before prescribing, you move from empiric treatment to precision‑guided therapy.

After treatment, repeat breath testing provides a quantifiable measure of bacterial eradication, helping guide decisions about recurrence risk and further treatment needs.​

In the ACG Clinical Guidelines, 76% of IBS subjects with an initially positive breath test who normalized after rifaximin were classified as responders based on the primary FDA outcome measure.

Breath testing both predicted response and confirmed eradication.​

How CDI Supports Treatment‑Guided Testing

🔵Dual‑gas measurement (hydrogen and methane) to identify SIBO and IMO patterns that guide antibiotic selection​
🔵24‑hour turnaround on results for timely treatment decisions​
🔵Pre‑ and post‑treatment testing to confirm eradication and help reduce recurrence risk​
🔵North American Consensus‑aligned protocols to ensure reliable, clinically validated results​
🔵MyGI Gateway tracking to monitor patient testing history and treatment response over time​

When IBS symptoms overlap with SIBO, objective testing helps distinguish who is more likely to respond to antibiotics from who isn’t.

That’s not just diagnostic clarity—it’s therapeutic strategy.​
Breath test before treatment → identify SIBO → predict antibiotic response → confirm eradication.

👉 Questions about using breath testing to guide antibiotic therapy decisions? Contact Provider Relations at providerservices@commdx.com—we’ll walk through pre‑ and post‑treatment testing protocols together.

📘 Read the full article: https://commdx.com/breath-testing-a-reliable-compass-in-navigating-sibo-diagnosis-and-post-treatment-evaluation/

01/29/2026

Chronic belly pain, bloating, and diarrhea in a pediatric patient. Is it SIBO? IMO? Malabsorption? Symptoms alone won’t tell you.

In children, these complaints look remarkably similar across conditions.

Research shows that 72% of pediatric SIBO cases present with abdominal pain, 54% with bloating, and 50% with constipation—yet these same symptoms appear in IBS, functional dyspepsia, and food intolerances.​

Without objective testing, treatment becomes guesswork.

Families cycle through elimination diets and empiric therapies while kids continue to struggle.​

The Case for Objective Testing

Hydrogen and methane breath testing provides the diagnostic clarity that symptoms can’t. When pediatric patients with suspected SIBO or IMO receive breath test‑guided treatment, over 70% show symptom resolution or significant improvement.​

The difference?

Accurate diagnosis first, targeted treatment second.

How CDI Supports Pediatric Breath Testing

CDI’s Hydrogen and Methane 6‑Tube Lactulose Breath Test is specifically designed for pediatric patients:​

Non‑invasive, at‑home collection reduces stress and eliminates the need for sedation or endoscopy​
6‑tube pediatric protocol tailored to smaller patients while maintaining diagnostic accuracy​
Measures both hydrogen and methane to detect SIBO, IMO, and identify gas patterns that guide treatment​
Validated sample stability supports reliable results across real‑world shipping and storage conditions for up to two weeks post‑collection​
Comprehensive carbohydrate testing (fructose, lactose, sucrose) to assess malabsorption alongside SIBO/IMO​

When the test is accurate and the prep is clear, families get answers. And clinicians can treat the cause, not just the symptoms.​

📘 Explore pediatric testing:
https://commdx.com/pediatric-breath-testing-for-sibo-imo/